Based on electrophysiological, neurochemical and neuropharmacological approaches, it is
currently accepted that serotonin (5-HT) and dopamine (DA) function to promote waking (W) …

Parkinson's disease is a neurodegenerative disorder that affects approximately 1% of
people over the age of 60 years. Levodopa is standard, and often initial, therapy for patients …

In older persons, sleep complaints in the form of insomnia and daytime drowsiness are
highly prevalent and are associated with adverse outcomes. The underlying mechanisms …

Excessive daytime sleepiness (EDS) can affect 20–50% of patients with Parkinson's disease
(PD), whereas sleep attacks (SA), which are sleep episodes without prodroma, seem …

It is now accepted that disorders of sleep are an integral part of neurodegenerative diseases
but for many years they were not considered a relevant part of these diseases. Many …

Apomorphine, a short-acting dopamine D 1 and D 2 receptor agonist, was the first dopamine
receptor agonist used to treat Parkinson's disease. Subcutaneous apomorphine is currently …

Sleep disturbances in patients with Parkinson's disease (PD) are common, are often severe,
and are typically underrecognized and ineffectively treated. After the recognition that some …

Objectives: The primary aim of this study was to determine how Parkinson's disease (PD)
affects driving performance. It also examined whether changes in driver safety were related …

Dopamine receptor agonists are indicated for the symptomatic treatment of early, moderate
or advanced Parkinson's disease as well as for the reduction of levodopa-related motor …

To estimate short-term rates of intolerable side effects and psychosis, data from all treated
subjects in prospective and retrospective studies of depression (253 subjects from 8 studies) …